Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


14 Items
Title  Creator  Group name  Publishing year 
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer Desroys du Roure et al. EquipePM 2024-01-30
Rapid communication: insights into the role of extracellular vesicles during Auger radioimmunotherapy Karam et al. EquipeJPP 2023
Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness Ursino et al. EquipeNB 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer Rabia et al. EquipeJC 2023
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures Larbouret et al. EquipeELC 2021-09-15
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival Chauvin et al. EquipeCG 2021-07
Anti-Müllerian hormone (AMH) autocrine signaling promotes survival and proliferation of ovarian cancer cells Chauvin et al. EquipeCTCS 2021-01-26
[A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response] Gros et al. EquipeNB Feb 2020
[Anti-tumor monoclonal antibodies: new insights to elicit a long-term immune response] Deligne and Gros EquipeNB Dec 2019
Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies Perrot et al. EquipeNB May 21, 2019
PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody They et al. EquipeNB 2017
IL-21 promotes the development of a CD73-positive V?9V?2 T cell regulatory population Barjon et al. EquipeEJ 2017
Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity Bastid et al. PlateformePP2I Mar 2015
14 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés